| Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies C Chester, MF Sanmamed, J Wang, I Melero Blood, The Journal of the American Society of Hematology 131 (1), 49-57, 2018 | 405 | 2018 |
| Natural killer cell immunomodulation: targeting activating, inhibitory, and co-stimulatory receptor signaling for cancer immunotherapy C Chester, K Fritsch, HE Kohrt Frontiers in immunology 6, 150517, 2015 | 215 | 2015 |
| Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies MF Sanmamed, C Chester, I Melero, H Kohrt Annals of Oncology 27 (7), 1190-1198, 2016 | 205 | 2016 |
| Androgen deprivation therapy and future Alzheimer’s disease risk KT Nead, G Gaskin, C Chester, S Swisher-McClure, JT Dudley, NJ Leeper, ... Journal of Clinical Oncology 34 (6), 566, 2016 | 205 | 2016 |
| Targeting CD137 enhances the efficacy of cetuximab HE Kohrt, AD Colevas, R Houot, K Weiskopf, MJ Goldstein, P Lund, ... The Journal of clinical investigation 124 (6), 2668-2682, 2014 | 199 | 2014 |
| Barcoding of live human peripheral blood mononuclear cells for multiplexed mass cytometry HE Mei, MD Leipold, AR Schulz, C Chester, HT Maecker The Journal of Immunology 194 (4), 2022-2031, 2015 | 165 | 2015 |
| Association between androgen deprivation therapy and risk of dementia KT Nead, G Gaskin, C Chester, S Swisher-McClure, NJ Leeper, NH Shah JAMA oncology 3 (1), 49-55, 2017 | 156 | 2017 |
| Boosting cancer immunotherapy with anti-CD137 antibody therapy A Yonezawa, S Dutt, C Chester, J Kim, HE Kohrt Clinical Cancer Research 21 (14), 3113-3120, 2015 | 148 | 2015 |
| 4-1BB agonism: adding the accelerator to cancer immunotherapy C Chester, S Ambulkar, HE Kohrt Cancer immunology, immunotherapy 65, 1243-1248, 2016 | 143 | 2016 |
| Algorithmic tools for mining high-dimensional cytometry data C Chester, HT Maecker The Journal of Immunology 195 (3), 773-779, 2015 | 114 | 2015 |
| Rationale for anti-CD137 cancer immunotherapy A Makkouk, C Chester, HE Kohrt European journal of cancer 54, 112-119, 2016 | 111 | 2016 |
| Immunotherapeutic approaches to ovarian cancer treatment C Chester, O Dorigo, JS Berek, H Kohrt Journal for immunotherapy of cancer 3, 1-10, 2015 | 95 | 2015 |
| Strategic combinations: the future of oncolytic virotherapy with reovirus X Zhao, C Chester, N Rajasekaran, ZX He, HE Kohrt Molecular cancer therapeutics 15 (5), 767-773, 2016 | 69 | 2016 |
| Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment N Rajasekaran, C Chester, A Yonezawa, X Zhao, HE Kohrt ImmunoTargets and therapy, 91-100, 2015 | 65 | 2015 |
| Cardiorespiratory fitness, physical activity and cancer mortality in men B Vainshelboim, J Müller, RM Lima, KT Nead, C Chester, K Chan, ... Preventive medicine 100, 89-94, 2017 | 52 | 2017 |
| Cardiorespiratory fitness and cancer incidence in men B Vainshelboim, J Müller, RM Lima, KT Nead, C Chester, K Chan, ... Annals of epidemiology 27 (7), 442-447, 2017 | 38 | 2017 |
| Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors C Chester, A Marabelle, R Houot, HE Kohrt Current opinion in immunology 33, 1-8, 2015 | 34 | 2015 |
| Three BTK-specific inhibitors, in contrast to ibrutinib, do not antagonize rituximab-dependent NK-cell mediated cytotoxicity N Rajasekaran, M Sadaram, J Hebb, I Sagiv-Barfi, S Ambulkar, ... Blood 124 (21), 3118, 2014 | 27 | 2014 |
| Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity F Souza-Fonseca-Guimaraes, SJ Blake, A Makkouk, C Chester, HE Kohrt, ... Oncoimmunology 5 (7), e1192740, 2016 | 20 | 2016 |
| Biomarker characterization using mass cytometry in a phase 1 trial of urelumab (BMS-663513) in subjects with advanced solid tumors and relapsed/refractory B-cell non-Hodgkin … C Chester, S Chang, JF Kurland, I Sagiv-Barfi, D Czerwinski, A Rajapaksa, ... Journal of Clinical Oncology 32 (15_suppl), 3017-3017, 2014 | 20 | 2014 |
